Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, lab services specialist Genoptix (Nasdaq: GXDX) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Genoptix's business and see what CAPS investors are saying about the stock right now.

Genoptix facts

Headquarters (Founded) Carlsbad, Calif. (1999)
Market Cap $341.4 million
Industry Health-care services
Trailing-12-Month Revenue $196.94 million
Management

Founder/CEO Dr. Tina Nova

CFO Douglas Schuling

Return on Equity (Average, Past 3 Years) 25.8%
Cash/Debt $138.6 million / $0
Competitors

Bio-Reference Labs (Nasdaq: BRLI)

Genzyme (Nasdaq: GENZ)

LabCorp (NYSE: LH)


Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 98% of the 691 members who have rated Genoptix believe the stock will outperform the S&P 500 going forward. These bulls include All-Star TheGrtGdOM, who is ranked in the top 15% of our community, and KMillionaire.

Late last year, TheGrtGdOM brought Genoptix's improving price to our community's attention:

Recovering from a very significantly excessive sell-off. It is still in the right place at the right time as health care reform will equal more people getting health care they need. When a stock is half of what it recently was without reason to believe anything different about the company's long term prospects, then it is a good time to buy.

Despite a soaring price over the past three months, Genoptix shares are still off 50% from their 52-week highs set in late April. Currently, Genoptix trades at an almost unbelievably low EV/EBITDA of 4.3, representing a clear discount to rivals Bio-Reference Labs (11.1), Genzyme (25.6), and LabCorp (9.1).

CAPS member KMillionaire is cautiously bullish:

This is a speculative play on my part. Their earnings growth is consistent with the idea that this is a potentially great growth stock. I wonder if they can keep that up, though. The company lowered their guidance and the price plummeted -- why does the share price get so shaken up by a little bad news? Risky; speculative.

Nonetheless, investor sentiment seems to be high, and it is priced cheap. That's about all one needs to know, for a stock like this. There is money to be made ... just be careful.

What do you think about Genoptix, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Laboratory of America Holdings is a Motley Fool Stock Advisor pick. The Fool owns shares of Bio-Reference Laboratories. Motley Fool Alpha owns shares of Laboratory of America Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.